Zigakibart Biosimilar - Anti-TNFSF13 mAb - Research Grade
Species
Homo sapiens
Expression system
XtenCHO
Purity
>90% by SDS-PAGE.
Buffer
0.01M PBS, pH 7.4.
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
anti-TNFSF13, TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1
Reference
PX-TA2099
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG4-kappa
Clonality
Monoclonal Antibody
Description of Zigakibart Biosimilar - Anti-TNFSF13 mAb - Research Grade
Introduction
Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade is a novel monoclonal antibody (mAb) that has been developed as a biosimilar to the anti-TNFSF13 mAb. This biosimilar has been designed to target the TNFSF13 protein, also known as B-cell activating factor (BAFF), which is a key regulator of B-cell survival and maturation. In this article, we will provide a detailed description of the structure, activity, and potential applications of Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade.
Structure of Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade
Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to the TNFSF13 protein, while the constant regions provide stability and effector functions.
The antibody has a molecular weight of approximately 150 kDa and is glycosylated, meaning it contains sugar molecules attached to the protein. This glycosylation is important for the stability and activity of the antibody.
Activity of Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade
Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade has been specifically designed to target the TNFSF13 protein, which is a cytokine that plays a crucial role in the development and survival of B-cells. This protein is overexpressed in autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, and is associated with increased B-cell activity and inflammation.
By binding to the TNFSF13 protein, Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade blocks its activity and prevents it from promoting B-cell survival and maturation. This leads to a decrease in the number of activated B-cells and a reduction in inflammation.
Potential Applications of Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade The potential applications of Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade are primarily in the treatment of autoimmune diseases. By targeting the TNFSF13 protein, this biosimilar has the potential to effectively treat diseases where B-cell activity and inflammation are major contributors.
In pre-clinical studies, Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade has shown promising results in reducing disease severity in models of rheumatoid arthritis and systemic lupus erythematosus. It has also been shown to have a favorable safety profile, with no significant adverse effects observed.
Conclusion
In conclusion, Zigakibart Biosimilar – Anti-TNFSF13 mAb – Research Grade is a novel monoclonal antibody that has been developed as a biosimilar to the anti-TNFSF13 mAb. It is composed of two heavy chains and two light chains and has a molecular weight of approximately 150 kDa. By targeting the TNFSF13 protein, this biosimilar has the potential to effectively treat autoimmune diseases by reducing B-cell activity and inflammation. Further studies and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar.
Reviews
There are no reviews yet.